TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29474934
Drug: 1-dose regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-dose regimen of HPV vaccine
Study: 29474934
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of HPV vaccine
Study: 24641624
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (8 g day(-1) containing 1.6 g day(-1) eicosapentaenoic acid + docosahexaenoic acid)
Study: 24641624
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic sunflower oil (8 g day(-1))
Study: 22160145
Drug: Darunavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir monotherapy
Study: 20802297
Drug: Darunavir/ritonavir triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir triple drug regimen
Study: 16782174
Drug: IL6 polymorphisms
Normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL6 polymorphisms (specifically the -572 G>C polymorphism)
Study: 15157691
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 3-4 weeks at anti-pain acupoints)
Study: 15157691
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (10 sessions over 3-4 weeks at placebo-points)
Study: 9442782
Drug: Latanoprost (0.005%)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) administered once daily for 6 months
Study: 9442782
Drug: Timolol (0.5%)
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol (0.5%) administered twice daily for 6 months
Study: 9442782
Drug: Latanoprost (0.005%)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) administered once daily for 18 months
Study: 9442782
Drug: Latanoprost (0.005%)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) administered once daily for 24 months
Study: 7992902
Drug: Esmolol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 0.75 mg/kg
Study: 2729906
Drug: Pipram (pipemidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipram (pipemidic acid) 200 mg daily at bedtime for 6 months
Study: 5100498
Drug: Gradual introduction
Normalized name: INTRODUCTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual introduction of treatment with levodopa
Study: 5100498
Drug: Rapid introduction
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid introduction of treatment with levodopa
Study: 5100498
Drug: Rate of
Normalized name: Citrate of Magnesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate of increasing the dose of levodopa
Study: 10899382
Drug: Mecamylamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine 20 mg
Study: 21644059
Drug: Scopolamine 0.5
Normalized name: scopolamine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.5 mg
Study: 27858074
Drug: Implant anchorage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant anchorage
Study: 21496949
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride (800 mg by mouth three times daily)
Study: 18779378
Drug: Cinaciguat (50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinaciguat (50-250 microg/h) administered intravenously for up to 4 hours
Study: 18779378
Drug: Cinaciguat (150-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinaciguat (150-250 microg/h) administered intravenously for up to 4 hours
Study: 11099083
Drug: 1-day intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day intramuscular ceftriaxone (50 mg/kg)
Study: 11099083
Drug: 3-day intramuscular
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intramuscular ceftriaxone (50 mg/kg/day)
Study: 9495995
Drug: Psychological suggestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological suggestion therapy
Study: 8394842
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Seleparina, CY 216) administered as 2 x 3,825 anti‐Xa international units subcutaneously on the day of surgery followed by a single daily 3,825 anti‐Xa international units injection for 7 days.
Study: 8394842
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Seleparina, CY 216).
Study: 2941473
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (active medication)
Study: 26880010
Drug: Conventional NAM
Normalized name: Ling Nam Ultra Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional NAM treatment (Group 1, n = 6)
Study: 20483885
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose)
Study: 2404841
Drug: Doxorubicin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (20 mg/m2 day 1 and 8) in combination with PCOP regimen (cyclophosphamide 400 mg/m2 day 1 and 8, vincristine 1.4 mg/m2 day 1 and 8, procarbazine 80 mg/m2 day 1 to 14, prednisone 60 mg/m2 day 1 to 5)
Study: 2404841
Drug: Doxorubicin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (20 mg/m2 day 1 and 8)
Study: 6776543
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg or occasionally 4 mg/day)
Study: 31488360
Drug: Lomustine-temozolomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomustine-temozolomide (100 mg/m2 on day 1 plus 100-200 mg/m2 on days 2-6 for six 6-week courses)
Study: 31488360
Drug: Temozolomide (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (75 mg/m2 daily during radiotherapy plus six 4-week courses of temozolomide [150-200 mg/m2] on days 1-5)
Study: 18302810
Drug: Nabilone 0.5
Normalized name: nabilone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 0.5 mg
Study: 21461891
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate (800 mg) in fasting state
Study: 21461891
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate (800 mg) following ingestion of a high-fat meal
Study: 21461891
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate (800 mg) once daily until discontinuation (multiple doses)
Study: 17370489
Drug: Needle-pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-pricking therapy
Study: 17370489
Drug: Medication (domiphen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (domiphen and HCG)
Study: 11837987
Drug: Folic acid,
Normalized name: folic acid, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid, alone or in combination with vitamin B12 and vitamin B6
Study: 9522322
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (100 IU/day) with calcium supplementation (1000 mg/day)
Study: 9522322
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg/day) with placebo intranasal spray
Study: 8425809
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin lotion applied twice daily
Study: 8425809
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks)
Study: 3675694
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg + ambroxol 60 mg t.i.d. (n = 8)
Study: 3675694
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg t.i.d. (n = 8)
Study: 4950563
Drug: Typhoid vaccine
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid vaccine (control)
Study: 25308804
Drug: Longer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer and stronger post-induction therapy for T cell ME WBC patients
Study: 25308804
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for B-ALL ME WBC patients
Study: 25308804
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for patients with WBC <200 × 10(9) /l
Study: 8389406
Drug: Liquid diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid diet with soluble fiber (21 g/L)
Study: 2831114
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg once daily, doubled if BP not controlled after 4 weeks
Study: 2831114
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP not controlled after 4 weeks
Study: 30903459
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH), Fraxiparine (0.4 ml, 3800 IU/day) for 2 days
Study: 30903459
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban 10 mg/day for 2 days
Study: 30903459
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban 20 mg/day for 2 days
Study: 28356142
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg (400 IU) of vitamin D3 supplementation
Study: 28356142
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg (1200 IU) of vitamin D3 supplementation
Study: 30735912
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg)
Study: 14640934
Drug: 17 alpha‐progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha‐progesterone caproate (17P) 250 mg/week i.m.
Study: 31397369
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment and human albumin (HA) infusions (40 g twice weekly for the first 2 weeks, then 40 g weekly for up to 18 months)
Study: 31397369
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (SMT) alone
Study: 31397369
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment and human albumin (HA) infusions
Study: 24508841
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with gemcitabine and carboplatin (GC)
Study: 22897339
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antiarrhythmic drug (AAD) in the first 3 months postablation
Study: 20493783
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (OROS‐MPH) at doses of 18, 36, or 54 mg
Study: 16002810
Drug: High-DHA algal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-DHA algal oil (approximately 200 mg DHA/d)
Study: 12435860
Drug: rhEPO (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke
Study: 12435860
Drug: rhEPO administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO administered within 5 hours of symptom onset
Study: 2673316
Drug: Nicardipine 60
Normalized name: niCARdipine 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 60 mg twice daily for 4 weeks
Study: 327942
Drug: Beclomethasone aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone aerosol given intranasally for 3 weeks (active drug)
Study: 30916450
Drug: Multi-strategic memory
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strategic memory training (MMT) - 10 weekly 90-min sessions
Study: 26105531
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP) treatment following accidental dural puncture (ADP)
Study: 22496352
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - either nicotine patch or nicotine gum for 5 weeks
Study: 21752257
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (20 sessions over 30 weeks)
Study: 21752257
Drug: Short Term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short Term Psychoanalytic Therapy (30 sessions over 30 weeks)
Study: 19174696
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily with compliance-enhancing program
Study: 19174696
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily without compliance-enhancing program
Study: 19174696
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily with compliance-enhancing program in statin-naive patients
Study: 19174696
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily without compliance-enhancing program in statin-naive patients
Study: 17096684
Drug: Mizoribine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine 12 mg kg(‐1) day(‐1) (multiple-dose study)
Study: 17096684
Drug: Mizoribine 3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine 3, 6, 9, and 12 mg kg(‐1) (single-dose study)
Study: 17096684
Drug: Mizoribine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine 6 mg kg(‐1) day(‐1) once daily for 5 days (multiple-dose study)
Study: 17096684
Drug: Mizoribine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine 12 mg kg(‐1) day(‐1) twice daily for 7 days (multiple-dose study)
Study: 11696472
Drug: Intracoronary NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary NO synthase inhibition with N(G)‐monomethyl‐L‐arginine (L‐NMMA; 25 micromol/min)
Study: 7781205
Drug: L-arginine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (160 mumol/min i.v. for 3 hours)
Study: 2223361
Drug: Extradural administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural administration of methadone 5 mg
Study: 666305
Drug: Cefadroxil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (15 mg/kg)
Study: 21197490
Drug: Group-bar (splinted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-bar (splinted mini-implants with a prefabricated bar)
Study: 21197490
Drug: Group-ball (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-ball (two single ball-type mini-implants)
Study: 15668556
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection (40 mg of methylprednisolone acetate)
Study: 14506619
Drug: MgC-Cre (Magnesium-creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgC-Cre (Magnesium-creatine chelate) at 800 mg Mg and 5 g Cre per day for 2 weeks
Study: 14506619
Drug: MgO-Cre (Magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgO-Cre (Magnesium oxide plus creatine) at 800 mg Mg and 5 g Cre per day for 2 weeks
Study: 10382900
Drug: Dirithromycin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (two 250 mg tablets od)
Study: 6985742
Drug: iopronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopronic acid (4.5 g)
Study: 6985742
Drug: iopanoic acid
Normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iopanoic acid (3.0 g)
Study: 18835437
Drug: Typhoid vaccine
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid vaccine with psychological stress
Study: 18835437
Drug: Typhoid vaccine
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid vaccine with rest
Study: 7719221
Drug: Oral cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cancer patients with second cancers
Study: 2439823
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg bopindolol
Study: 2906897
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg bopindolol
Study: 29338142
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion of 5 mL/h plus 5 mL demand bolus doses with 10-minute lockout (group B/D)
Study: 29338142
Drug: Only demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only demand bolus doses of 5 mL with 10-minute lockout (group D)
Study: 24010876
Drug: CS21 barrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS21 barrier genital gel®
Study: 21981375
Drug: Topical aciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aciclovir
Study: 23107042
Drug: Metformin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (3 g daily)
Study: 2868899
Drug: Ro 31-1118
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 31-1118 (10 mg)
Study: 2868899
Drug: Ro 31-1118
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 31-1118 (20 mg)
Study: 2868899
Drug: Ro 31-1118
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 31-1118 (40 mg)
Study: 2868899
Drug: Ro 31-1118
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 31-1118 (80 mg)
Study: 2868899
Drug: Ro 31-1118
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 31-1118 (all doses)
Study: 27160412
Drug: THC:CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC:CBD oromucosal spray
Study: 24331983
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen/10 mg hydrocodone
Study: 20642326
Drug: 0.5-g progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-g progesterone vaginal rings (PVR)
Study: 20642326
Drug: 1-g progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-g progesterone vaginal rings (PVR)
Study: 12590007
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 microg/day)
Study: 14998844
Drug: Carboplatin 840
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy (60 Gy)
Study: 12421891
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of lysine aspirin for two weeks (5 patients)
Study: 12421891
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of lysine aspirin for six months (5 patients)
Study: 7863253
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg/day for one year (Group A)
Study: 7863253
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with nizatidine (Group B)
Study: 31724170
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy (administered every 2 weeks)
Study: 31724170
Drug: Dose-dense chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense chemotherapy with trastuzumab
Study: 31724170
Drug: Standard-interval chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-interval chemotherapy (administered every 3 weeks)
Study: 29998997
Drug: Yangyin Tiluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangyin Tiluo Decoction (YTD) for 4 weeks (200 mL of the decoction two times daily)
Study: 20843496
Drug: Mail reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mail reminder group (letter plus CDC Influenza Vaccine Information Statement)
Study: 16330297
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg IM single injection)
Study: 16330297
Drug: Haloperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (7.5 mg IM single injection)
Study: 16330297
Drug: Haloperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (7.5 mg IM multiple injections)
Study: 16330297
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg IM multiple injections)
Study: 11140808
Drug: l-carnitine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine (20 mg/kg)
Study: 10051966
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan (6 mg)
Study: 1946181
Drug: Alcohol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.0 g/kg)
Study: 30526051
Drug: Brinzolamide-brimonidine fixed
Normalized name: brimonidine / brinzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide-brimonidine fixed combination
Study: 25764777
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (neurodevelopmental rehabilitation and classic kinesiotherapy) plus botulinum toxin
Study: 25764777
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (neurodevelopmental rehabilitation and classic kinesiotherapy)